178 Temple Street, New Haven, Connecticut 06510, United States
.png/:/rs=h:320,cg:true,m/qt=q:95)
Qualifying Conditions
For Adults, Debilitating Medical Conditions Include:
- Cancer (Effective 2012)
- Glaucoma (Effective 2012)
- Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)
- Parkinson’s Disease (Effective 2012)
- Multiple Sclerosis (Effective 2012)
- Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
- Epilepsy (Effective 2012)
- Cachexia (Effective 2012)
- Wasting Syndrome (Effective 2012)
- Crohn’s Disease (Effective 2012)
- Post-Traumatic Stress Disorder (Effective 2012)
- Sickle Cell Disease (Effective 2016)*
- Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*
- Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*
- Amyotrophic Lateral Sclerosis (Effective 2016)*
- Ulcerative Colitis (Effective 2016)*
- Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*
- Cerebral Palsy (Effective 2016)
- Cystic Fibrosis (Effective 2016)
- Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
- Terminal Illness Requiring End-Of-Life Care (Effective 2016)
- Uncontrolled Intractable Seizure Disorder (Effective 2016)
- Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*
- Severe Rheumatoid Arthritis (Effective 2018)*
- Post Herpetic Neuralgia (Effective 2018)*
- Hydrocephalus with Intractable Headache (Effective 2018)*
- Intractable Headache Syndromes (Effective 2018)*
- Neuropathic Facial Pain (Effective 2018)*
- Muscular Dystrophy (Effective 2018)*
- Osteogenesis Imperfecta (Effective 2018)*
- Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*
- Interstitial Cystitis (Effective 2019)*
- MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*
- Vulvodynia and Vulvar Burning (Effective 2019)*
- Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
- Tourette Syndrome (Effective 2019)*
- Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*
- Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*
- Chronic Pancreatitis (Effective 2021)*
- Movement Disorders associated with Huntington Disease (Effective 2021)*
- Autism Spectrum Disorder (Effective 2024)^
- Female Orgasmic Difficulty/Disorder (Effective 2024)^
For Patients Under 18, Debilitating Medical Conditions Include:
- Cerebral Palsy (Effective 2016)
- Cystic Fibrosis (Effective 2016)
- Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
- Severe Epilepsy (Effective 2016)
- Terminal Illness Requiring End-Of-Life Care (Effective 2016)
- Uncontrolled Intractable Seizure Disorder (Effective 2016)
- Muscular Dystrophy (Effective 2018)*
- Osteogenesis Imperfecta (Effective 2018)*
- Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
- Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*
- Chronic Pancreatitis for patients whose pain is recalcitrant to standard medical management (Effective 2021)*
* Conditions were approved by the Regulation Review Committee via the recommendation of the Board of Physicians and Commissioner of Consumer Protection.
